基于对中国医药外资企业在华研发资金投入与本土企业研发资金投入的关系研究,为进一步提升医药本土企业研发投入提供参考。通过构建VAR模型,选取1995—2016年医药企业相关数据,对医药外资企业在华研发资金投入和医药本土企业研发资金投入的动态关联进行实证研究。结果显示：医药外资企业在华研发资金投入每增加1%,医药本土企业研发资金投入增加0.87%,反之不成立；且这种正向推动作用存在3年的滞后期。医药外资企业在华对研发的投入高于中国医药本土企业,且相比而言占有较大的比例,中国医药本土企业需要充分认识到这方面的差距与挑战,继续深化与外资企业合作交流,增强研发投入意识,促进自主创新能力的提升。

Based on the research on the relationship between the R&D investment of foreign pharmaceutical enterprises in China and the R&D investment of local enterprises, this paper provides a reference for further improving the R&D investment of local pharmaceutical enterprises. Through the construction of VAR model, the paper selects the relevant data of pharmaceutical enterprises from 1995 to 2016 to make an empirical study on the dynamic relationship between the R&D investment of foreign pharmaceutical enterprises in China and that of local pharmaceutical enterprises. The results show that for every 1% increase in R&D investment of foreign pharmaceutical enterprises in China, the R&D investment of local pharmaceutical enterprises increases by 0.87%, otherwise, it is not established; and this positive role has a lag of 3 years. The investment of foreign pharmaceutical enterprises in R&D in China is higher than that of local pharmaceutical enterprises, which accounts for a large proportion. Local pharmaceutical enterprises in China need to fully recognize the gap and challenges in this regard, continue to deepen cooperation and exchange with foreign enterprises, enhance the awareness of R&D investment, and promote the improvement of independent innovation ability.

F403.7；F272.3；R95

辽宁省科技厅自然科学重点基金项目“基于SEM的仿制药一致性评价综合方法的创新与应用研究”（20170540845）